[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autoimmune-bullous-dermatosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autoimmune-bullous-dermatosis":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100562149","identification-of-cutaneous-and-blood-biomarkers-predictive-of-response-to-systemic-treatments-during-chronic-inflammatory-skin-diseases-100562149",false,"NCT06599411","Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases","Identification Des Marqueurs Biologiques cutanés et Sanguins prédictifs de réponse Aux Traitements systémiques au Cours Des Maladies cutanées Inflammatoires Chroniques","ImmuneSkinBank","Inclusion Criteria:\n\nPatients:\n\n* Age\\>18 years\n* Informed consent signed by the patient\n* Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis, cutaneaous vasculitis, autoimmune bullous dermatosis\n* Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification \\[1\\], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).\n\nHealthy controls :\n\n* Age\\>18 years\n* Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants\n* Informed consent signed by the patient\n* Absence of known cutaneous inflammatory disease.\n\nExclusion Criteria:\n\n* Under guardianship or curatorship\n* Pregnant or breastfeeding woman\n* Lack of affiliation with a social security system\n* Current systemic treatment with immunosupressant (including corticosteroid therapy) or an immunomodulator or received within the last 3 months.",true,"ALL","18 Years",{"count":21,"type":22},830,"ESTIMATED","OBSERVATIONAL","Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.\n\nThe main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.\n\nThe secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.",[26,27,28,29,30,31,32,33,34,35,36,37],"Atopic Dermatitis","Psoriasis","Hidradenitis Suppurativa","Lichen Planus","Cutaneous Lupus","Dermatomyositis","Cutaneaous Scleroderma","Neutrophilic Dermatosis","Cutaneous Granulomatosis","Active Leprosy","Autoimmune Bullous Dermatosis","Cutaneous Vasculitis","RECRUITING","2026-06-10",{"date":41,"type":42},"2026-06-12","ACTUAL",{"date":44,"type":42},"2025-10-20",{"date":46,"type":22},"2045-10-20",{"name":48,"class":49},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":50},"100518949","coagulopathy-of-immunodermatologic-diseases-100518949","NCT06037187","Coagulopathy of Immunodermatologic Diseases","Coagulopathy of Immunodermatologic Diseases The Molecular, Prognostic, and Therapeutic Implications of Crosstalk Between Coagulation, Fibrinolysis, and Inflammation in Immune-Mediated Skin Diseases","Inclusion Criteria:\n\n1. For the study group: diagnosis of immune-mediated skin disease including but not limited to bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, cutaneous lupus erythematosus, dermatomyositis\n2. For control group: no diagnosis of immune-mediated skin\n3. For study group: receiving care from one or more of the Principal or Secondary Investigators\n\nExclusion Criteria:\n\n1. Unfit to provide consent\n2. P2Y12 inhibitor use in the past 4 weeks\n3. History of internal malignancy prior to enrolling in the study or suspected internal\u002Fsystemic malignancy during time of the study (i.e. will not exclude pre-malignant or local, early stage cutaneous malignancies)\n4. Major surgery within 4 weeks of the study or trauma (e.g., accident-causing bone fracture) within 4 weeks of the study\n5. Other autoimmune diseases not in remission defined as flare in the last 12 weeks\n6. If patient is unable to provide detailed history and if we do not have sufficient history on record.\n7. Less than 19 years of age","19 Years",{"count":60,"type":22},39,"This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active\u002Fpoorly controlled immune-mediated skin diseases and mild\u002Flatent\u002Fwell-controlled immune-mediated skin diseases. A one-time sample from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy will also be collected to serve as control. Blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. The results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.",[36],"2026-05-08",{"date":65,"type":42},"2026-05-12",{"date":67,"type":42},"2023-05-09",{"date":69,"type":22},"2026-12",{"name":71,"class":49},"University of Nebraska",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":50},"100545879","clinico-biological-collection-of-autoimmune-dysimmune-or-auto-inflammatory-dermatological-diseases-100545879","NCT06387654","Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases","Constitution of a Collection of Biological Samples With the Aim of Carrying Out Clinico-biological and Physiopathological Investigations of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases","TekAPo","Inclusion Criteria:\n\nSkin damage of documented or probable autoimmune, dysimmune or autoinflammatory origin.\n\nThe patients included may be adults or children, and will be:\n\n* Patients with autoimmune bullous dermatoses (pemphigus, pemphigoid and others),\n* Patients with systemic autoimmune diseases associated with skin damage (lupus, scleroderma, dermatomyositis for example),\n* Patients with cutaneous lupus\n* Patients with dysimmune skin diseases (psoriasis, eczema)\n* Patients with immuno-induced dermatological disorders or drug dermatitis\n* Patients receiving, or likely to receive, new, innovative therapies (new molecule on the market, checkpoint inhibitors, gene therapy, cell therapy, etc.).\n\nPatients with dermatological damage whose autoimmune, dysimmune or auto-inflammatory origin is suspected\n\nExclusion Criteria:\n\n* Patients under protective supervision (guardianship, curators)\n* Patients under 6 years old\n* Pregnant or breastfeeding woman","6 Years","99 Years",{"count":83,"type":22},800,"The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.",[36,86,87,88],"Dysimmune Dermatological Diseases","Auto-inflammatory Dermatological Diseases","Skin Diseases",[90,91,92,93,94,95,96],"auto-inflammatory dermatological diseases","Cutaneous lupus","scleroderma","dermatomyositis","psoriasis","eczema","new therapies","2026-03-16",{"date":99,"type":42},"2026-03-17",{"date":101,"type":42},"2024-05-06",{"date":103,"type":22},"2034-04",{"name":105,"class":49},"University Hospital, Toulouse"]